DanCann Pharma A/S has submitted application to the Danish Medicines Agency for EU-GMP-approval for Biotech Pharm1
COPENHAGEN, Denmark, 9 February 2022 – DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”), a Danish company powered by cannabinoids, hereby announce that the Company submitted its application for EU-GMP-approval to the Danish Medicines Agency.In April, DanCann Pharma pressed the start button in the Company’s first production facility, Biotech Pharm1 in Ansager. Now the Company is ready to be inspected from the Danish Medicines Agency in order to be approved according to EU-GMP standards. The approval is expected to be in place by the half year of 2022. Biotech Pharm1 is